SCHEMBL1010640

SCHEMBL1010640

CC(C)(Oc1ccccc1CCCNCC(Oc1ccccc1)c1nc2ccccc2o1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.40
PPARA Q07869 9/20 0.40
PPARD Q03181 4/20 0.40
ADRB3 P13945 3/20 0.36
MTNR1A P48039 5/20 0.35
MTNR1B P49286 5/20 0.35
PTPN1 P18031 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012141 0.95 PPARA (0.40) PPARGPPARAPPARDADRB3PTPN1
SCHEMBL1010703 0.94 PPARG (0.39) PPARGPPARAPPARDADRB3PTPN1
SCHEMBL1010020 0.90 PPARA (0.39) PPARGPPARAPPARDPTPN1KDM4E
SCHEMBL1012350 0.89 MAPT (0.39) PPARGPPARAPPARDADRB3PTPN1
SCHEMBL1010742 0.87 PPARG (0.51) PPARGPPARAPPARDADRB3KDM4E
SCHEMBL1010312 0.86 MAPT (0.37) PPARGPPARAPPARDMTNR1AMTNR1B
SCHEMBL1010612 0.86 PPARA (0.56) PPARGPPARAPPARDADRB3
SCHEMBL1009876 0.83 ADRB3 (0.56) PPARGPPARAPPARDADRB3KDM4E
SCHEMBL6543074 0.83 PPARG (0.39) PPARGPPARAPPARDADRB3MTNR1A
SCHEMBL1009685 0.82 PPARG (0.54) PPARGPPARAPPARDADRB3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.